ReviewCancers2019
Proteomic Biomarkers for the Detection of Endometrial Cancer.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 91 citations in OpenAlex.
- AKR1B1 and AKR1B10 as Potential Prognostic Biomarkers of Endometrial Cancer.International journal of molecular sciences · 2026Article
- Cancer detection via one-shot learning: integrating gene expression and genomic mutation analysis.BMC bioinformatics · 2025Article
- Evaluating plasma adipokines and their cognate receptors as biomarkers for non-invasive diagnosis of endometrial cancer.Bioscience reports · 2025Article
- Review
- Acid phosphatase type 6 promotes endometrial cancer progression via activating PI3K/AKT pathway.Molecular biology reports · 2025Article
- Comparison of intravenous contrast-enhanced ultrasound and magnetic resonance imaging in preoperative staging of endometrial carcinoma.American journal of cancer research · 2025Article
- Plasma-based proteomic profiling identifies the distinct regulation of proteins in hyperplasia and endometrial cancer.BMC cancer · 2024Article
- Identification and validation of serum metabolite biomarkers for endometrial cancer diagnosis.EMBO molecular medicine · 2024Article
- Enhancing intracellular mRNA precise imaging-guided photothermal therapy with a nucleic acid-based polydopamine nanoprobe.Analytical and bioanalytical chemistry · 2024Article
- Proteomics: Unraveling the Cross Talk Between Innate Immunity and Disease Pathophysiology, Diagnostics, and Treatment Options.Advances in experimental medicine and biology · 2024Review
- An ultrasound-based radiomics model for survival prediction in patients with endometrial cancer.Journal of medical ultrasonics (2001) · 2023Article
- Identification of Potentially Novel Molecular Targets of Endometrial Cancer Using a Non-Biased Proteomic Approach.Cancers · 2023Article
- The crucial value of serum ferritin in assessing high-risk factors and prognosis for patients with endometrial carcinoma.BMC women's health · 2023Article
- Upgrading Treatment and Molecular Diagnosis in Endometrial Cancer-Driving New Tools for Endometrial Preservation?International journal of molecular sciences · 2023Review
- Quantitative SWATH-based proteomic profiling of urine for the identification of endometrial cancer biomarkers in symptomatic women.British journal of cancer · 2023Article
- Application value of Ki67 and serum CA125 in the deep myometrial invasion of endometrial adenocarcinoma.BMC cancer · 2023Article
- Multiomic Approaches for Cancer Biomarker Discovery in Liquid Biopsies: Advances and Challenges.Biomarker insights · 2023Review
- Protein biomarkers in cervicovaginal lavages for detection of endometrial cancer.Biomarker research · 2022Article
- Ion Channels in Endometrial Cancer.Cancers · 2022Review
- Urine CA125 and HE4 for the Triage of Symptomatic Women with Suspected Endometrial Cancer.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Endometrial cancer is the leading gynaecological malignancy in the western world and its incidence is rising in tandem with the global epidemic of obesity. Early diagnosis is key to improving survival, which at 5 years is less than 20% in advanced disease and over 90% in early-stage disease. As yet, there are no validated biological markers for its early detection. Advances in high-throughput technologies and machine learning techniques now offer unique and promising perspectives for biomarker discovery, especially through the integration of genomic, transcriptomic, proteomic, metabolomic and imaging data. Because the proteome closely mirrors the dynamic state of cells, tissues and organisms, proteomics has great potential to deliver clinically relevant biomarkers for cancer diagnosis. In this review, we present the current progress in endometrial cancer diagnostic biomarker discovery using proteomics. We describe the various mass spectrometry-based approaches and highlight the challenges inherent in biomarker discovery studies. We suggest novel strategies for endometrial cancer detection exploiting biologically important protein biomarkers and set the scene for future directions in endometrial cancer biomarker research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.